acarbose, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
albiglutide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
alogliptin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
aripiprazole, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
asenapine, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
aspirin increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.
atazanavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
azilsartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
benazepril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects. Monitor blood glucose.
bitter melon increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.
insulin aspart, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
candesartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
captopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood glucose. Monitor blood glucose.
chlorpropamide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
cinnamon increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.
ciprofibrate increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.
ciprofloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.
clozapine, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
insulin aspart, dapagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.dapagliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
darunavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
insulin aspart and deflazacort both decrease serum potassium. Use Caution/Monitor.
dexfenfluramine increases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Dexfenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.
dichlorphenamide and insulin aspart both decrease serum potassium. Use Caution/Monitor.
disopyramide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and disopyramide may require insulin dosage adjustment and increased glucose monitoring.
dulaglutide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
empagliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.
enalapril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
eprosartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
ertugliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin.
ethinylestradiol decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Oral contraceptives may decrease hypoglycemic effects of antidiabetics by impairing glucose tolerance. Monitor for glycemic control in diabetic patients.
exenatide injectable solution, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
exenatide injectable suspension, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
fenfluramine increases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Fenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.
fenofibrate increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.
fenofibrate micronized increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.
fenofibric acid increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.
fleroxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
fluoxetine increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and fluoxetine may require insulin dosage adjustment and increased glucose monitoring.
fosamprenavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
fosinopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
gemfibrozil increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.
gemifloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
glimepiride, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
glipizide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
glucagon decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus.
glucagon intranasal decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus.
glyburide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
iloperidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
imidapril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
indinavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
irbesartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
isocarboxazid increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.
ketotifen, ophthalmic, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Combination may result in thrombocytopenia (rare). Monitor CBC.
lanreotide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring.
levofloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
linagliptin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
linezolid increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.
liraglutide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
lisinopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
lithium, insulin aspart. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.
lonapegsomatropin decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents.
lopinavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
losartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
lurasidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
magnesium salicylate increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.
marijuana decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor.
mecasermin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.
metformin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
methyltestosterone increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. It is important to monitor all patients with type 2 diabetes on antidiabetic agents receiving androgens for changes in glycemic control. Potential for hypoglycemia.
metoclopramide intranasal increases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Increased GI motility by metoclopramide may increase delivery of food to the intestines and increase blood glucose. Monitor blood glucose and adjust insulin dosage regimen as needed.
insulin aspart, metreleptin.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.
miglitol, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
moexipril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
moxifloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
nadolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance. Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.
nateglinide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
nelfinavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
niacin decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Concomitant use of insulin and niacin may require insulin dosage adjustment and increased glucose monitoring.
octreotide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring.
ofloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
olanzapine, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
olmesartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
opuntia ficus indica increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
paliperidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
pasireotide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring.
pentamidine, insulin aspart. unspecified interaction mechanism. Use Caution/Monitor. Pentamidine may cause either hypoglycemia or hyperglycemia followed by the opposing effect. Insulin dosage adjustment and increased glucose monitoring may be required.
perindopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
phenelzine increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.
pindolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance. Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.
insulin aspart increases toxicity of pioglitazone by unknown mechanism. Use Caution/Monitor. Insulin may increase the fluid retention associated with thiazolidinediones (peroxisome proliferator-activated receptor [PPAR]-gamma agonists).pioglitazone, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
procarbazine increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.
propranolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance. Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.
quetiapine, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
quinapril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
ramipril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
rasagiline increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.
risperidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
ritonavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
insulin aspart increases toxicity of rosiglitazone by unknown mechanism. Use Caution/Monitor. Insulin may increase the fluid retention associated with thiazolidinediones (peroxisome proliferator-activated receptor [PPAR]-gamma agonists).rosiglitazone, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
sacubitril/valsartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
salsalate increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.
saquinavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
saxagliptin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
selegiline increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.
selegiline transdermal increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.
semaglutide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk.
shark cartilage increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.
sitagliptin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.
sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.
insulin aspart and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease serum potassium. Modify Therapy/Monitor Closely.
somapacitan decreases effects of insulin aspart by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. .
somatropin decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor.
sulfadiazine increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and sulfonamide antibiotics may require insulin dosage adjustment and increased glucose monitoring.
sulfamethoxypyridazine increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.
sulfisoxazole increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and sulfonamide antibiotics may require insulin dosage adjustment and increased glucose monitoring.
telmisartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
testosterone intranasal increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication.
timolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance. Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.
tipranavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
tolazamide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
tolbutamide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
trandolapril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.
tranylcypromine increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.
triamcinolone acetonide injectable suspension decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.
valsartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.
xipamide decreases levels of insulin aspart by increasing renal clearance. Use Caution/Monitor.
ziprasidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
agrimony increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
American ginseng increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
amitriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
amoxapine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
anamu increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.
aspirin rectal increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
aspirin/citric acid/sodium bicarbonate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
balsalazide increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
bendroflumethiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.
bexarotene increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
budesonide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
chlorothiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.
chlorthalidone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.
choline magnesium trisalicylate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
chromium increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
clomipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
clonidine decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.clonidine, insulin aspart. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.
coenzyme Q10 increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.
cornsilk increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
cortisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
cyclopenthiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.
damiana decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.
danazol increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
deflazacort decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
desipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
devil's claw increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
dexamethasone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
diflunisal increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
doxepin increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
elderberry increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (in vitro research).
eucalyptus increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.
fludrocortisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
fluoxymesterone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
fo-ti increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
forskolin increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Colenol, a compound found in Coleus root, may stimulate insulin release.
gotu kola increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
guanfacine decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.guanfacine, insulin aspart. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.
gymnema increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
horse chestnut seed increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
hydrochlorothiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.
hydrocortisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
imipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
indapamide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.
isoniazid decreases effects of insulin aspart by unspecified interaction mechanism. Minor/Significance Unknown.
juniper increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
lofepramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
lycopus increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).
maitake increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (animal research).
maprotiline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
mesalamine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
mesterolone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
methyclothiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.
methylprednisolone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
metolazone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.
nettle increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
nortriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
ofloxacin, insulin aspart. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.
oxandrolone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
oxymetholone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
panax ginseng increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
pegvisomant increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
potassium acid phosphate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
potassium chloride increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
potassium citrate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
prednisolone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
prednisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.
protriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
sage increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
salicylates (non-asa) increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
Siberian ginseng increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
sulfasalazine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
testosterone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
testosterone buccal system increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
testosterone topical increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
tongkat ali increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia.
trazodone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
trimipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
vanadium increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
willow bark increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.
FAQs
What is the indication for insulin aspart? ›
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus. Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals.
What drugs interact with NovoLog? ›- albuterol.
- amlodipine.
- aspirin.
- atorvastatin.
- carvedilol.
- furosemide.
- gabapentin.
- Lantus (insulin glargine)
...
Conditions:
- low blood sugar.
- low amount of potassium in the blood.
- liver problems.
- decreased kidney function.
- rash and/or itching over the whole body.
- shortness of breath.
- wheezing.
- dizziness.
- blurred vision.
- fast heartbeat.
- sweating.
- weakness.
NovoLog® is a rapid-acting insulin that helps lower mealtime blood sugar spikes in adults and children with diabetes. It has been proven to help control high blood sugar in people with diabetes when taken with a long-acting insulin.
When is insulin aspart given? ›Fiasp®—insulin aspart with dose timing flexibility at mealtime; Fiasp® can be administered at the beginning of the meal or within 20 minutes after starting a meal. See Fiasp® Important Safety Information below. View Fiasp® Prescribing Information.
What drug class is insulin aspart? ›Insulin aspart falls into category B. In animal studies, pregnant animals were given insulin aspart, and some babies had problems. It is very important to maintain control of your blood sugar levels during pregnancy.
What class of drug is NovoLog? ›NOVOLOG (insulin aspart injection) is a rapid-acting human insulin analog used to lower blood glucose.
Do you take NovoLog before or after meals? ›NovoLog is a rapid-acting form of insulin that should be injected below the skin 5 to 10 minutes before meals. Have food ready before injection. After injecting the in- sulin, do not skip a meal or delay eating.
What is the difference between NovoLog and aspart? ›Humalog is the brand-name version of insulin lispro, and Novolog is the brand-name version of insulin aspart. These drugs both help manage blood glucose (sugar) in people with type 1 and type 2 diabetes. Humalog and Novolog are both rapid-acting.
What is the action of NovoLog? ›
The primary activity of NovoLogis the regulation of glucose metabolism. Insulins, including NovoLog, bind to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver.
Can you overdose on insulin aspart? ›The main danger associated with insulin overdose is the resultant hypoglycemia and its effects on the central nervous system; hypokalemia, hypophosphatemia, and hypomagnesemia also can develop with excess insulin administration.
What type of insulin is insulin aspart? ›NovoLog (insulin aspart) is a fast-acting insulin that controls blood sugar around meal times for both type 1 and type 2 diabetes.
What is the difference between aspart and regular insulin? ›Short-acting insulin analogues (aspart, glulisine, and lispro) are thought to be better than regular human insulin due to faster absorption and faster onset of action, mimicking better the physiological prandial insulin peak of people without diabetes [14, 15] and leading to lower postprandial glucose levels [16].
What drug class is insulin aspart? ›Insulin aspart falls into category B. In animal studies, pregnant animals were given insulin aspart, and some babies had problems. It is very important to maintain control of your blood sugar levels during pregnancy.
What is the difference between insulin lispro and insulin aspart? ›What is the difference between insulin lispro and insulin aspart? Insulin lispro and insulin aspart are two generic forms of fast-acting insulin. However, they are chemically different with slightly different onsets of action. Insulin lispro works within 15 minutes while insulin aspart works within five to 10 minutes.